Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Olaparib and Paclitaxel in Gastric Cancer
NCT03579784Phase 2Active, not recruiting
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in gastric cancer (GC). Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03579784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579784.